Dolcontin (Morphine Sulfate)

What Is Dolcontin and What Is It Used For?

Dolcontin contains morphine sulfate pentahydrate, one of the most potent naturally occurring opioid analgesics known to medicine. Morphine has been used for pain management for over two centuries and remains one of the cornerstones of severe pain treatment according to the World Health Organization (WHO) analgesic ladder. Dolcontin is classified as a Step 3 analgesic — reserved for severe pain that does not respond adequately to non-opioid medications (Step 1) or weak opioids (Step 2).

The extended-release formulation of Dolcontin is specifically engineered to provide a gradual, sustained release of morphine over approximately 12 hours per dose. This controlled-release mechanism ensures stable plasma morphine concentrations, reducing the fluctuations between peak and trough levels that occur with immediate-release formulations. The result is more consistent pain relief with fewer dosing intervals, which improves patient compliance and quality of life.

The primary indication for Dolcontin is severe pain such as cancer-related pain. Cancer pain is often chronic, progressive, and multifactorial, requiring around-the-clock opioid therapy to maintain adequate analgesia. However, Dolcontin may also be prescribed in selected cases of severe non-malignant chronic pain when all other treatment options have been exhausted and the benefits clearly outweigh the risks of long-term opioid therapy.

Dolcontin is manufactured by Mundipharma and is available in multiple strengths (5 mg, 10 mg, 30 mg, 60 mg, 100 mg, and 200 mg), allowing physicians to titrate the dose precisely to each patient's individual pain management needs. The tablets are colour-coded by strength for safety purposes and bear identifying markings to prevent dispensing errors.

Morphine works by binding to mu-opioid receptors in the central nervous system (brain and spinal cord), altering both the perception of pain and the emotional response to it. In addition to its analgesic effects, morphine has several other pharmacological actions including sedation, euphoria, respiratory depression, cough suppression, and reduced gastrointestinal motility — the latter being responsible for the common side effect of constipation.

What Should You Know Before Taking Dolcontin?

Before starting treatment with Dolcontin, your prescribing physician will conduct a thorough assessment of your medical history, current medications, and overall health status. Because morphine is a potent opioid with significant risks including respiratory depression, addiction, and potentially fatal interactions, it is essential that both you and your doctor carefully weigh the benefits against the risks.

Contraindications

You must not take Dolcontin if you have any of the following conditions:

• Hypersensitivity to morphine or any excipient in the formulation
• Severe respiratory depression leading to hypoxia and/or hypercapnia (elevated carbon dioxide in the blood)
• Head injury or conditions with increased intracranial pressure, as morphine may mask neurological signs
• Paralytic ileus (complete bowel obstruction), severe abdominal pain, or delayed gastric emptying
• Acute liver disease or severe hepatic impairment
• Seizure disorders, as morphine may lower the seizure threshold
• Severe chronic obstructive pulmonary disease (COPD) or severe bronchial asthma
• Acute intoxication with alcohol, sedatives, hypnotics, or other central nervous system (CNS) depressants

Warnings and Precautions

Inform your doctor before starting Dolcontin if you have or have had any of the following conditions, as they may require dose adjustments, additional monitoring, or alternative treatment:

• Cor pulmonale (right heart failure due to chronic lung disease)
• Hypothyroidism (underactive thyroid gland)
• Hepatic or renal impairment — morphine is metabolised in the liver and excreted by the kidneys; impairment of either organ can lead to accumulation and toxicity
• Brain injury, altered consciousness, or increased intracranial pressure of unknown origin
• Hypotension due to reduced blood volume (hypovolaemia)
• Biliary or urinary tract disorders, as morphine may cause spasm of smooth muscle
• Pancreatitis (inflammation of the pancreas)
• Inflammatory bowel disease
• Conditions with excessive airway secretions
• Prostatic hypertrophy (enlarged prostate), which may worsen urinary retention
• Adrenocortical insufficiency (Addison's disease)
• Pre-existing constipation

You may be at greater risk of dependence or misuse if:

• You or a family member has a history of alcohol, prescription drug, or illicit substance misuse
• You are a smoker
• You have a history of depression, anxiety, or other psychiatric conditions

Warning signs of developing dependence include needing the medication for longer than prescribed, taking more than the recommended dose, using it for reasons other than pain relief (e.g., to feel calm or to sleep), and repeated unsuccessful attempts to reduce use. If you notice any of these signs, speak to your doctor about the best treatment approach.

Stop taking Dolcontin and seek immediate medical attention if you experience signs of a severe allergic reaction (anaphylaxis): swelling of the face, tongue, or throat; difficulty swallowing; hives; or difficulty breathing.

Contact your doctor if you notice any of the following during treatment:

• Opioid-induced hyperalgesia — increased sensitivity to pain despite higher doses, which may require a change in medication
• Adrenal insufficiency — symptoms include weakness, fatigue, loss of appetite, nausea, vomiting, and low blood pressure
• Hormonal effects — decreased libido, erectile dysfunction, or amenorrhoea (absence of menstruation) due to suppressed sex hormone production
• Pancreatitis or biliary spasm — severe upper abdominal pain radiating to the back, nausea, vomiting, or fever
• Severe skin reactions (AGEP) — blistering, widespread skin peeling, or pus-filled spots accompanied by fever, usually within the first 10 days of treatment

Pregnancy and Breastfeeding

Dolcontin should not be used during pregnancy unless the potential benefits clearly outweigh the risks to the foetus. Morphine crosses the placental barrier, and prolonged use during pregnancy may cause neonatal opioid withdrawal syndrome (NOWS) in the newborn, which requires specialised medical management. Symptoms in the newborn may include irritability, hyperactivity, abnormal sleep patterns, high-pitched crying, tremors, vomiting, diarrhoea, and failure to gain weight.

Morphine passes into breast milk. Breastfeeding is not recommended during Dolcontin therapy due to the risk of sedation, respiratory depression, and potentially fatal effects in the nursing infant. Always consult your doctor before using Dolcontin if you are pregnant, planning to become pregnant, or breastfeeding.

Driving and Operating Machinery

Dolcontin can significantly impair your alertness, reaction time, and cognitive function. You should not drive or operate heavy machinery until you know how Dolcontin affects you. This impairment is particularly pronounced at the start of treatment, during dose changes, and when combined with alcohol or other CNS depressants. You are personally responsible for assessing whether you are fit to perform tasks requiring sustained attention.

Lactose Content

Dolcontin extended-release tablets (5 mg, 10 mg, 30 mg, and 60 mg) contain lactose. If you have been diagnosed with an intolerance to certain sugars, contact your doctor before taking this medicine.

How Does Dolcontin Interact with Other Drugs?

Morphine is metabolised primarily in the liver and interacts with a wide range of pharmaceutical agents. It is critically important that you inform your doctor about all medications you are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and recreational substances. The following tables summarise the most clinically significant drug interactions.

Major Interactions (Avoid Combination or Use Extreme Caution)

Moderate Interactions (Use with Caution)

This list is not exhaustive. Always inform your doctor and pharmacist about every medication you are taking, including over-the-counter products and herbal supplements such as St John's Wort, valerian, or kava.

What Is the Correct Dosage of Dolcontin?

The dosage of Dolcontin is strictly individualised by the prescribing physician. There is no standard fixed dose for all patients. The appropriate dose depends on the severity and nature of the pain, the patient's previous opioid exposure, age, weight, hepatic and renal function, and overall clinical status. Before initiating treatment and at regular intervals thereafter, your doctor will discuss what to expect, when and how long to take the medication, when to seek medical advice, and when treatment should be stopped.

Adults

For patients who are opioid-naive (not currently taking opioid medications), treatment typically begins at a low dose (e.g., 10–30 mg every 12 hours) with careful upward titration as needed. For patients being converted from other opioids, the physician will calculate an equianalgesic dose using established opioid conversion tables to ensure a smooth transition without under- or over-dosing.

There is no defined maximum dose of morphine for cancer pain — the dose is limited by side effects rather than a ceiling effect. Some patients with severe cancer pain may require several hundred milligrams per day. However, dose escalation should always be gradual and under close medical supervision, with careful assessment at each step of the balance between pain relief and adverse effects.

Elderly Patients

Older adults are generally more sensitive to the effects of opioids due to age-related changes in body composition, hepatic metabolism, and renal clearance. Lower starting doses are recommended, with slower dose titration intervals. Enhanced monitoring for respiratory depression, excessive sedation, confusion, and falls is essential in this population. The adage "start low, go slow" is particularly applicable to opioid prescribing in the elderly.

Children

Dolcontin is not routinely recommended for children. When paediatric opioid therapy is necessary, it should be prescribed and supervised by a specialist in paediatric pain management with appropriate weight-based dosing and careful monitoring. The safety and efficacy of extended-release morphine formulations in younger children have not been extensively studied.

Renal and Hepatic Impairment

Patients with kidney disease may accumulate active morphine metabolites (particularly morphine-6-glucuronide, which is pharmacologically active and renally excreted), significantly increasing the risk of prolonged sedation and respiratory depression. Dose reduction and increased dosing intervals are typically required. In liver disease, morphine metabolism is impaired due to reduced hepatic first-pass metabolism, necessitating lower doses and careful monitoring. Dolcontin is contraindicated in acute hepatic disease.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is nearly time for the next scheduled dose, skip the missed dose and continue with your regular schedule. Never take a double dose to compensate for a missed one, as this significantly increases the risk of overdose.

Overdose

Signs and symptoms of morphine overdose include:

• Pinpoint pupils (miosis) — one of the hallmark signs of opioid overdose
• Severe respiratory depression — slow, shallow, or absent breathing, which may progress to respiratory arrest
• Loss of consciousness progressing to coma
• Severe hypotension (dangerously low blood pressure)
• Circulatory collapse in severe cases
• Aspiration pneumonia from inhalation of vomit
• Toxic leukoencephalopathy (a rare brain injury associated with severe overdose)

The specific antidote for opioid overdose is naloxone, which is administered by emergency medical personnel. Naloxone rapidly reverses the effects of morphine, including respiratory depression, but its duration of action is shorter than that of morphine — repeated doses or continuous infusion may be necessary, particularly with extended-release formulations like Dolcontin.

What Are the Side Effects of Dolcontin?

Like all medications, Dolcontin can cause side effects, though not everyone experiences them. The side effect profile of morphine is well-characterised through decades of clinical use. Many common side effects (particularly nausea and drowsiness) tend to diminish after the first few days of treatment as the body develops a degree of tolerance. However, constipation is a notable exception — it typically persists throughout the duration of therapy and usually requires concurrent preventive laxative treatment from the outset.

Your doctor will proactively manage expected side effects. For constipation, stimulant laxatives (such as senna or bisacodyl) and/or osmotic laxatives (such as macrogol) are commonly prescribed alongside opioid therapy. For nausea, anti-emetics may be prescribed for the first 1–2 weeks until tolerance develops.

If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. Reporting side effects helps healthcare authorities monitor the ongoing safety profile of medicines. In the European Union, you can report side effects to your national medicines agency. In the United States, report to the FDA MedWatch programme. In the United Kingdom, report via the Yellow Card scheme.

What Happens If You Stop Taking Dolcontin?

If you have been taking Dolcontin for an extended period, your body will have developed physical dependence on morphine. This is a normal physiological adaptation — not the same as addiction — but it means that abruptly stopping the medication will trigger withdrawal symptoms.

Do not stop taking Dolcontin without consulting your doctor. When it is appropriate to discontinue treatment, your doctor will create a gradual tapering schedule, slowly reducing the dose over weeks to months to minimise withdrawal symptoms and ensure your pain remains adequately managed during the transition.

Withdrawal symptoms may include:

• Generalised body aches and muscle pain
• Tremors and shaking
• Diarrhoea and abdominal cramps
• Nausea and vomiting
• Flu-like symptoms (runny nose, sweating, chills)
• Rapid heartbeat (tachycardia) and palpitations
• Dilated pupils
• Intense anxiety, irritability, and restlessness
• Insomnia and sleep disturbances
• Intense craving for the medication

The severity and duration of withdrawal symptoms depend on the dose and duration of Dolcontin therapy. Higher doses and longer treatment periods typically result in more intense withdrawal. With a well-managed tapering plan, most patients can discontinue opioid therapy with manageable discomfort. Your doctor may also prescribe adjunctive medications to alleviate specific withdrawal symptoms during the tapering process.

How Should You Store Dolcontin?

Proper storage of Dolcontin is essential not only for maintaining the medication's efficacy but also for safety, given that morphine is a controlled substance with significant abuse potential. Accidental ingestion by a child can be fatal.

• Temperature: Store at or below 25°C (77°F). Do not refrigerate or freeze.
• Children: Keep out of sight and reach of children at all times. Accidental ingestion of even a single dose by a child can be fatal.
• Security: Store in a secure, locked location to prevent theft and diversion. Opioid medications are frequently targeted for misuse.
• Expiry: Do not use after the expiry date printed on the packaging (EXP). The expiry date refers to the last day of that month.
• Disposal: Do not dispose of unused tablets by flushing or throwing into household waste. Return unused or expired medication to a pharmacy for safe disposal through an authorised take-back programme. This protects the environment and prevents diversion.

What Does Dolcontin Contain?

Each Dolcontin extended-release tablet contains morphine sulfate pentahydrate as the active ingredient. The morphine sulfate content corresponds to the following amounts of free morphine base:

Inactive ingredients (excipients): Lactose anhydrous, cetostearyl alcohol, hydroxyethyl cellulose, talc, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide (E171).

Additional colourants by strength:

• 5 mg, 30 mg, 60 mg, 100 mg: Iron oxide (E172)
• 200 mg: Brilliant Blue FCF (E133), Quinoline Yellow (E104)

All tablets are biconvex (slightly curved on both sides) with a diameter of 7.3 mm (5–100 mg strengths) or 8.8 mm (200 mg strength). They are supplied in blister packs of various sizes (10, 14, 25, 30, 49, 90, or 100 tablets). Not all pack sizes may be available in your country.

References

This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:

1. World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018.
2. European Medicines Agency (EMA). Summary of Product Characteristics: Morphine Sulfate Extended-Release Tablets. EMA; 2024.
3. U.S. Food and Drug Administration (FDA). Morphine Sulfate Extended-Release Tablets Prescribing Information. FDA; 2023.
4. British National Formulary (BNF). Morphine. NICE; 2025. Available from: bnf.nice.org.uk
5. Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain — an overview of Cochrane reviews. Cochrane Database of Systematic Reviews. 2017;7:CD012592.
6. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1–95.
7. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: A Clinical Practice Guideline. J Pain. 2016;17(2):131–157.
8. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68.

Editorial Team

This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians, pharmacists, and medical researchers with expertise in pain medicine, pharmacology, and clinical therapeutics.

Editorial Standards: All content follows the iMedic Editorial Standards, including the GRADE evidence framework. No commercial funding is accepted. Content is updated regularly to reflect the latest evidence and guideline changes.